MedTrace Logo

Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women

NCT05854992 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 68419

Last updated 2024-12-02

No results posted yet for this study

Summary

Researchers are evaluating the safety of triptan treatment of migraine in individuals with elevated cardiovascular risk and in pregnant women.

Conditions

Interventions

DRUG

Acute migraine treatment with any prescribed triptans

Sumatriptan, treximet (sumatriptan/naproxen combination), zolmitriptan, naratriptan, rizatriptan, almotriptan, eletriptan, and frovatriptan. No restriction on dose, frequency, duration, or delivery routes.

DRUG

Standard of care management of acute migraine without triptans

Any standard of care management without triptans

Sponsors & Collaborators

  • Agency for Healthcare Research and Quality (AHRQ)

    collaborator FED

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Mohammad Murad, MD · Mayo Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2024-11-01
Completion
2024-11-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05854992 on ClinicalTrials.gov